SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001213900-17-002501
Filing Date
2017-03-16
Accepted
2017-03-16 18:18:18
Documents
1
Period of Report
2017-03-14

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT f4031417dave_actinium.html 4  
1 OWNERSHIP DOCUMENT f4031417dave_actinium.xml 4 4061
  Complete submission text file 0001213900-17-002501.txt   5496
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Issuer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 4 WATER STREET EDISON NJ 08820
Business Address
DAVE KAUSHIK J (Reporting) CIK: 0001522751 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36374 | Film No.: 17695898